Supplementary Materials

This PDF file includes:

  • Fig. S1. Generation of high-titer retroviral clone.
  • Fig. S2. Preclinical validation of 1RG-CART cell product.
  • Fig. S3. Recruitment and treatment on study.
  • Fig. S4. Count recovery after lymphodepletion and 1RG-CART administration.
  • Fig. S5. Assessment of response to 1RG-CART in bone marrow trephines for patient 25/010.
  • Fig. S6. Assessment of intensity scores in isolated regions of interest by normalization to liver uptake on 123I-mIBG scans before and after 1RG-CART.
  • Fig. S7. PD-L1 expression and T cell infiltration in tumor biopsies before and after 1RG-CART treatment.
  • Fig. S8. GD2 expression in tumor cells in bone marrow and biopsies after 1RG-CART.
  • Fig. S9. 1RG-CART cell product characteristics in patients with and without immune activation and antitumor activity.
  • Table S1. Eligibility criteria.
  • Table S2. Characteristics of patients recruited on study.
  • Table S3. 1RG-CART cell product dose and phenotype.
  • Table S4. Serum cytokine measurements.
  • Tables S5. Scoring of 123I-mIBG scans before and after 1RG-CART treatment.
  • Table S6. Scoring of PD-L1 expression in the tumor microenvironment before and after 1RG-CART treatment.
  • Table S7. GD2 expression in tumor samples at baseline and after 1RG-CART.

[Download PDF]